![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Peginterferon Lambda-1A (Lambda) Compared
With Peginterferon Alfa-2A (Alfa) in Treatment-
Naive Patients With HCV Genotypes 2 or 3: First
SVR24 Results From EMERGE Phase IIb
|
|
|
Reported by Jules Levin
S Zeuzem, S Arora, B Bacon, T Box, M Charlton, M Diago, D Dieterich,
R Esteban Mur, G Everson, M Fallon, P Ferenci, R Flisiak, J George, R Ghalib,
N Gitlin, A Gladysz, S Gordon, S Greenbloom, T Hassanein, I Jacobson, L Jeffers, K Kowdley, E Lawitz, S Lee, B Leggett, S Lueth, D Nelson, P Pockros, M Rodriguez-Torres, V Rustgi, L Serfaty, M Sherman, M Shiffman, R Sola, M Sulkowski, H Vargas, J Vierling, B Yoffe, L Ishak, D Fontana, D Xu, J Lester, T Gray, A Horga, J Hillson, JC Lopez-Talavera, A Muir, on behalf of the EMERGE Study Group
47th EASL Congress, Barcelona, Spain
April 18-22, 2012
Oral Abstract 1435
![EASL1.gif](../images/042012/042012-2/EASL1.gif)
![EASL2.gif](../images/042012/042012-2/EASL2.gif)
![EASL3.gif](../images/042012/042012-2/EASL3.gif)
![EASL4.gif](../images/042012/042012-2/EASL4.gif)
![EASL5.gif](../images/042012/042012-2/EASL5.gif)
![EASL6.gif](../images/042012/042012-2/EASL6.gif)
![EASL7.gif](../images/042012/042012-2/EASL7.gif)
![EASL8.gif](../images/042012/042012-2/EASL8.gif)
![EASL9.gif](../images/042012/042012-2/EASL9.gif)
![EASL10.gif](../images/042012/042012-2/EASL10.gif)
![EASL11.gif](../images/042012/042012-2/EASL11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|